Lambert-Eaton myasthenic syndrome - Revision history

Luca.ratibondi: /* Epidemiology */

2020-01-05T22:14:08Z

Epidemiology

← Older revision		Revision as of 22:14, 5 January 2020
Line 7:		Line 7:
	**50% of patients have concurrent small-cell lung cancer		**50% of patients have concurrent small-cell lung cancer
	*Syndrome can precede detection of malignancy by several years		*Syndrome can precede detection of malignancy by several years
			*Paraneoplastic syndrome in 60-70% of cases

	==Clinical Features==		==Clinical Features==
Line 36:		Line 37:
	*[[Acetylcholinesterase inhibitors]] (e.g. [[pyridostigmine]]) can improve symptoms		*[[Acetylcholinesterase inhibitors]] (e.g. [[pyridostigmine]]) can improve symptoms
	*Guanidine		*Guanidine
	*Aminopyridines		*Aminopyridines: 2-10 mg/day
	*[[IVIG]]		*[[IVIG]]
	*[[Glucocorticoids]]		*[[Glucocorticoids]]

ClaireLewis at 03:42, 3 October 2019

2019-10-03T03:42:38Z

← Older revision		Revision as of 03:42, 3 October 2019
Line 10:		Line 10:
	==Clinical Features==		==Clinical Features==
	*Often presents with alteration in gait or difficulty rising from a chair		*Often presents with alteration in gait or difficulty rising from a chair
	*Fluctuating symmetric weakness and fatigue, especially of proximal leg muscles		*Fluctuating symmetric [[weakness]] and fatigue, especially of proximal leg muscles
	*Improvement in strength with sustained or repeated exercise (in contrast to MG)		*Improvement in strength with sustained or repeated exercise (in contrast to MG)
	**Lambert sign: handshake strength increases over several seconds		**Lambert sign: handshake strength increases over several seconds
	*~~Myalgias~~		*[[Myalgia]]s
	*Muscle stiffness (especially in hip and shoulders)		*Muscle stiffness (especially in hip and shoulders)
	*~~Paresthesias~~		*[[Paresthesia]]s
	*Metallic taste		*Metallic taste
	*Eye movements are unaffected		*Eye movements are unaffected
	*Sensory examination normal		*Sensory examination normal
	*Symmetrical muscle weakness and fatiguability often beginning in lower extremities
	*Autonomic dysfunction (dry mouth, erectile dysfunction)		*Autonomic dysfunction (dry mouth, erectile dysfunction)
	*Compared with ~~myastenia~~ gravis, LEMS begins with lower extremities weakness and rarely begins with extraocular muscle weakness		*Compared with myasthenia gravis, LEMS begins with lower extremities weakness and rarely begins with extraocular muscle weakness
	*Respiratory failure can occur in late stages of the disease		*[[Respiratory failure]] can occur in late stages of the disease
	*Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms		*Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms

Line 39:		Line 38:
	*Aminopyridines		*Aminopyridines
	*[[IVIG]]		*[[IVIG]]
	*Glucocorticoids		*[[Glucocorticoids]]
	*[[Plasma exchange]]		*[[Plasma exchange]]

Kxl328: /* Clinical Features */

2018-10-17T04:25:12Z

Clinical Features

← Older revision		Revision as of 04:25, 17 October 2018
Line 21:		Line 21:
	*Symmetrical muscle weakness and fatiguability often beginning in lower extremities		*Symmetrical muscle weakness and fatiguability often beginning in lower extremities
	*Autonomic dysfunction (dry mouth, erectile dysfunction)		*Autonomic dysfunction (dry mouth, erectile dysfunction)
	*Compared with myastenia gravis, ~~ELS~~ begins with lower extremities weakness and rarely begins with extraocular muscle weakness		*Compared with myastenia gravis, LEMS begins with lower extremities weakness and rarely begins with extraocular muscle weakness
	*Respiratory failure can occur in late stages of the disease		*Respiratory failure can occur in late stages of the disease
	*Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms		*Paraneoplastic and autoimmune form of LEMS have similar signs and symptoms

Mholtz: Text replacement - "==References== " to "==References== "

2017-07-18T09:43:47Z

Text replacement - "==References== " to "==References== <references/> "

← Older revision		Revision as of 09:43, 18 July 2017
Line 51:		Line 51:

	==References==		==References==
			<references/>
	[[Category:Neurology]]		[[Category:Neurology]]

ClaireLewis: /* Management */

2017-04-03T17:54:08Z

Management

← Older revision		Revision as of 17:54, 3 April 2017
Line 40:		Line 40:
	*[[IVIG]]		*[[IVIG]]
	*Glucocorticoids		*Glucocorticoids
	*Plasma exchange		*[[Plasma exchange]]

	==Disposition==		==Disposition==

ClaireLewis: /* Management */

2016-10-10T01:11:03Z

Management

← Older revision		Revision as of 01:11, 10 October 2016
Line 38:		Line 38:
	*Guanidine		*Guanidine
	*Aminopyridines		*Aminopyridines
	*IVIG		*[[IVIG]]
	*Glucocorticoids		*Glucocorticoids
	*Plasma exchange		*Plasma exchange

ClaireLewis: /* Management */

2016-10-05T05:00:06Z

Management

← Older revision		Revision as of 05:00, 5 October 2016
Line 35:		Line 35:
	==Management==		==Management==
	*Supportive (progression to respiratory or bulbar failure is rare)		*Supportive (progression to respiratory or bulbar failure is rare)
	*Acetylcholinesterase inhibitors (e.g. pyridostigmine) can improve symptoms		*[[Acetylcholinesterase inhibitors]] (e.g. [[pyridostigmine]]) can improve symptoms
	*Guanidine		*Guanidine
	*Aminopyridines		*Aminopyridines

Rossdonaldson1: Text replacement - " esp " to " especially "

2016-07-30T22:47:08Z

Text replacement - " esp " to " especially "

← Older revision		Revision as of 22:47, 30 July 2016
Line 10:		Line 10:
	==Clinical Features==		==Clinical Features==
	*Often presents with alteration in gait or difficulty rising from a chair		*Often presents with alteration in gait or difficulty rising from a chair
	*Fluctuating symmetric weakness and fatigue, ~~esp~~ of proximal leg muscles		*Fluctuating symmetric weakness and fatigue, especially of proximal leg muscles
	*Improvement in strength with sustained or repeated exercise (in contrast to MG)		*Improvement in strength with sustained or repeated exercise (in contrast to MG)
	**Lambert sign: handshake strength increases over several seconds		**Lambert sign: handshake strength increases over several seconds

Neil.m.young: Text replacement - "==Diagnosis==" to "==Evaluation=="

2016-07-22T19:55:03Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

← Older revision		Revision as of 19:55, 22 July 2016
Line 28:		Line 28:
	{{Weakness DDX}}		{{Weakness DDX}}

	==~~Diagnosis~~==		==Evaluation==
	*Diagnosis is generally a clinical diagnosis		*Diagnosis is generally a clinical diagnosis
	*Confirmation testing for VGCC antibodies		*Confirmation testing for VGCC antibodies

Neil.m.young: Text replacement - "==Treatment==" to "==Management=="

2016-07-07T16:30:43Z

Text replacement - "==Treatment==" to "==Management=="

← Older revision		Revision as of 16:30, 7 July 2016
Line 33:		Line 33:
	*Neurophysiologic testing		*Neurophysiologic testing

	==~~Treatment~~==		==Management==
	*Supportive (progression to respiratory or bulbar failure is rare)		*Supportive (progression to respiratory or bulbar failure is rare)
	*Acetylcholinesterase inhibitors (e.g. pyridostigmine) can improve symptoms		*Acetylcholinesterase inhibitors (e.g. pyridostigmine) can improve symptoms